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S120 VALUE IN HEALTH - MAY 2020Household SES was defined based on income, education and occupation. Neigh-
borhood SES was defined by the percent of households living in poverty in the child’s
school district. Utilizing sampling weights and accounting for sample design, log-
binomial regression models were fitted to estimate the association between neigh-
borhood SES and obesity prevalence and to test whether this association varied by
household SES. Predicted probabilities of overweight/obesity were estimated for
each combination of household and neighborhood SES. Results: In adjusted models,
low neighborhood SES was associated with increased prevalence of overweight/
obesity (RR:1.84, 95%CI 1.48, 2.29). This association varied significantly by household
SES (p-value of the interaction = 0.002). The multiplicative interaction indicated that
having low neighborhood SES was associated with increased probability of over-
weight/obesity among children from high SES-households (Prevalence Ratio
(PR)neighborhood SES:1.87, 95%CI 1.51,2.30) but having low neighborhood SES did was
not associated with additionally increased probability of obesity for children from
low SES-household (PRneighborhood SES:1.10, 95%CI 0.92,1.32). Children with either low
SES-households or low neighborhood SES had the highest predicted probabilities of
overweight/obesity, but the effects were not multiplicative. Conclusions: There is
statistical evidence of interaction between the two dimensions of SES. However,
lower SES in either of them is enough to place children at high risk of overweight or
obesity. Higher levels in one dimension do not mitigate the association between low
resources on the other dimension and childhood overweight/obesity.
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Objectives: A high prevalence of multimorbidity (co-occurrence of more than one
chronic condition, excluding diabetes) is reported in adults with diabetes. Multi-
morbidity can negatively affect DCM due to competing demands and prioritization of
clinical management. The objective of this study is to examine the associations of
multimorbidity to DCM and assess changes in DCM over a five-year period. Meth-
ods: We used a pooled cross-sectional design with two independent cross-sections
(2011 and 2015) of the Medical Expenditure Panel Survey, representative of the
noninstitutionalized population in the US. Adults (age . 18 years) with professional
diagnosed diabetes and who completed Diabetes Care Survey (DCS) (N= 4,291; N
2011 = 2,116; N 2015 = 2,175) were included. DCS is a self-administered paper-based
survey that queried DCM practices in the last 12 months (HbA1c test, blood
cholesterol test, feet checked for soreness and irritation, dilated-pupil eye-exami-
nation, and flu vaccination). Unadjusted, adjusted, and stratified logistic regressions
were used to achieve the study objectives. Adjusted analyses controlled for biolog-
ical, socio-economic, healthcare access, health status, and behavioral characteristics.
All analyses accounted for the complex survey design. Results: 85.1% reported
multimorbidity; adults with multimorbidity had poor physical, mental health, had
higher rates of chronic pain, obesity, and physical inactivity. Adjusted analyses
indicated that adults with multimorbidity were more likely to participate in all DCM
recommendations except foot examination (example: HbA1c AOR = 1.68, 95% CI:
1.26, 2.24; Cholesterol level AOR = 1.71, 95% CI: 1.21, 2.41) compared to those without
multimorbidity. Trend analysis showed no statistically significant differences in the
DCM patterns for those with multimorbidity. Conclusions: Eight in 10 adults with
diabetes reported multimorbidity. Those with multimorbidity were more likely to
receive recommended DCM services, which can be explained by “the surveillance
hypothesis” (i.e. more likely to access health services).
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Objectives: To estimate the therapeutic inertia in the treatment of patients with type
2 diabetes (DMT2) in a cardiovascular risk management cohort from the Caribbean
region of Colombia Methods: Retrospective cohort study. A total of 128,263 patients
enrolled to a cardiovascular prevention program between June 2015 to December
2018 was considered as the population. Patients .=18 years with antidiabetic drugs
dispensed were included. Therapeutic inertia was defined as the failure to initiate or
intensify antidiabetic therapy in a timely manner according to the clinical practice
guideline (CPG) in Colombia. Date of diagnosis was defined as the first record of
HAb1c.= 6.5%. Inertia at diagnosis was defined as no appropriated treatment in a 1-
month period after date of diagnosis (monotherapy if HAb1c ,8% or combined
therapy if HAb1c.= 8%). Inertia at follow-up was defined as no intensification of
therapy between 3-6 months after diagnosis in patients with failure in the initial
treatment (HAb1c . = 7%) Results: A total of 4,411 patients were identified with a
mean (SD) HAb1c of 8.8% 6 12.9 and 1,965(44.5%) had complicated DMT2 atdiagnosis. Of these, 1,090 (55.4%) were treated only with Metformin. Inertia at
diagnosis was observed in 1,875 patients (42.5%; IC 95% 41.0 - 43.9). At follow-up,
1,340 (30.3%) patients had failure to the initial treament (HAb1c: 7.8% 6 4.4). Of
these, 241 (17.9%) had no intensification in their pharmacological treatment. Inertia
at follow-up was observed in 1,776 patients (40.2%; 95% CI 38.8 - 41.7). Prevalence of
inertia at diagnosis and follow-up was 17.1% (95% CI 16, 0 – 18.2%) and 82.7% (95% CI
81.6% - 83.8%) of patients had inertia either at diagnosis or follow-up. Con-
clusions: Therapeutic inertia was highly prevalent in our study. This should be
considered in the evaluation of the effectiveness of current delivery of healthcare in
this population
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Objectives: The risk of developing complications increases with years lived with
type-2 diabetes and age leading to further deterioration in quality of life. The aim of
our study was to determine the epidemiological disease burden of non-insulin-
dependent diabetes with complications. Methods: Data were derived from the
financial database of the Hungarian National Health Insurance Fund Administration
(NHIFA), for the year 2018. Data analysed included annual patient numbers, case
numbers and prevalence of care utilisation per 100.000 population according to age
groups and sex. The following health insurance treatment categories were included
into our study: general practice care, home care, in- and outpatient care, medical
imaging, laboratory diagnostics, drugs and medical aids. Patients with non-insulin-
dependent diabetes with complications were identified with the following code of
the International Classification of Diseases 10th revision: E1180. Results: The highest
national patient numbers were in general practice care: 97,017 men, 109,758 women,
in total 206,775patients, followed by use of pharmaceuticals (66,568 men,72,841
women, in total 139,409 patients), and outpatient care (62,595 men, 67,946 women,
in total 130,541patients). Based on patient numbers in general practice care, prev-
alence in 100,000 among men was 2,076.7 patients, among women 2,149.3, in total
2,114.6 patients. Patients above age 55 accounted for 87.73%, those above 65
accounted for 64.69% and patients aged above 75 accounted for 32.46% of patient
numbers including all forms of care. Regarding sex, in general practice care 46.9 %
were men, 53.1 % were women, while in the use of pharmaceuticals 47.8 % were men
and 52.2 % were women. Conclusions: Regarding patients’ sex, there was no dif-
ference between men and women at the onset of the disease. Age was found to have
a significant impact upon prevalence of diabetes with complications.
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Objectives: The Center for Biologics Evaluation and Research Biologics Effectiveness
and Safety (BEST) Initiative sought to develop administrative claims-based defini-
tions, referred to as algorithms, for populations of interest. These algorithms will be
used in epidemiologic studies to evaluate biologics’ safety. The objective of this study
was to develop algorithms for diabetes mellitus (DM) as a study covariate, study
population, and outcome. Methods: Authors conducted a literature review using
PubMed. Findings were leveraged to develop initial algorithms that were mapped
from the International Classification of Diseases, Ninth Revision, Clinical Modification
to the Tenth Revision via forward–backward mapping using General Equivalence
Mappings. Clinical subject matter experts reviewed draft algorithms. Each algorithm
was characterized in the IBM® MarketScan® Research Databases via the IBM Mar-
ketScan Treatment Pathways tool or ad hoc programming. Descriptive statistics of
patients identified by each algorithm were generated for 2014–2017. Results: The
annual number of individuals who met the general (any) DM “Covariate” criteria
ranged from 76.8 to 78.8 individuals/1,000 enrolled/year, with a higher proportion of
males than females. Among a cohort of 71,039,547 patients, 109,342 (0.2%) and
1,141,553 (1.6%) met the “Population” criteria for type 1 DM (T1DM) and type II DM
(T2DM), respectively. Males represented 52.6% and 51.1% of those with T1DM and
T2DM, respectively. Results: from individual queries of codes in the “Outcome”
iteration suggest that the number of individuals identified by T2DM codes was
highest (3,500,744), followed by T1DM (354,579), other diabetes (270,337), and
secondary diabetes (109,150). Conclusions: Forward–backward mapping was used
to develop three new algorithms for DM. Though not validated, these algorithms
were applied to generate statistics on the frequency of reporting for each iteration
between 2014 and 2017. This effort should support subsequent epidemiologic studies
on the safety and effectiveness of biologics among an at-risk population in the United
States.
